C

    Cocrystal Pharma Inc (COCP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.16
    +0.06 (+5.45%)

    Market Cap: $21.19M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    76%(25/33)
    Avg Surprise
    +25.11%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.14 - $-0.14
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.17-25.0%
    60d ago$-0.17-25.0%
    30d ago$-0.17-25.0%
    7d ago$-0.17-25.0%
    Current$-0.14
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.23
    Range$-0.23 - $-0.23
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.23---
    Sep 26EST
    		-$-0.14---
    Jun 26
    Reported Aug 13
    		$-0.23$-0.17-35.29%Miss-15.0%
    Mar 26
    Reported May 15
    		$-0.17$-0.15-13.33%Miss+26.1%
    Dec 25
    Reported Dec 31
    		$-0.17$-0.17+2.86%Beat+46.9%
    Sep 25
    Reported Nov 14
    		$-0.19$-0.21+9.52%Beat+61.2%
    Jun 25
    Reported Aug 14
    		$-0.20$-0.30+33.33%Beat+62.3%
    Mar 25
    Reported May 15
    		$-0.23N/A+55.77%Beat+41.0%
    Dec 24
    Reported Mar 31
    		$-0.32$-0.53+39.62%Beat+27.3%
    Sep 24
    Reported Nov 13
    		$-0.49$-0.57+14.04%Beat-19.5%
    Jun 24
    Reported Aug 14
    		$-0.53$-0.48-10.42%Miss-6.0%
    Mar 24
    Reported May 13
    		$-0.39$-0.56+30.36%Beat+39.1%
    Dec 23
    Reported Mar 28
    		$-0.44$-0.60+26.67%Beat+20.0%
    Sep 23
    Reported Nov 13
    		$-0.41$-0.65+36.92%Beat+41.4%
    Jun 23
    Reported Aug 14
    		$-0.50$-0.47-6.38%Miss-8.7%
    Mar 23
    Reported May 15
    		$-0.64$-0.70+8.57%Beat-33.3%
    Dec 22
    Reported Mar 29
    		$-0.55$-0.73+24.66%Beat-14.6%
    Sep 22
    Reported Nov 14
    		$-0.70$-0.49-42.86%Miss-45.8%
    Jun 22
    Reported Aug 15
    		$-0.46$-0.52+11.54%Beat+4.2%
    Mar 22
    Reported May 11
    		$-0.48$-0.42-14.29%Miss+0.0%
    Dec 21
    Reported Mar 23
    		$-0.48$-0.48+0.00%Beat-100.0%
    Sep 21
    Reported Nov 15
    		$-0.48$-0.48+0.00%Beat+15.8%
    Jun 21
    Reported Aug 16
    		$-0.48$-0.42-14.29%Miss+39.2%
    Mar 21
    Reported May 17
    		$-0.48$-0.54+11.11%Beat+15.8%
    Dec 20
    Reported Mar 17
    		$-0.24$-0.48+50.00%Beat+60.0%
    Sep 20
    Reported Nov 16
    		$-0.57$-0.60+5.00%Beat+34.5%
    Jun 20
    Reported Aug 6
    		$-0.79$-0.48-64.58%Miss+2.5%
    Mar 20
    Reported May 14
    		$-0.57$-0.96+40.63%Beat+34.5%
    Dec 19
    Reported Mar 27
    		$-0.60$-0.84+28.57%Beat-276.5%
    Sep 19
    Reported Nov 12
    		$-0.87$-0.96+9.38%Beat-20.8%
    Jun 19
    Reported Aug 9
    		$-0.81$-0.84+3.57%Beat-35.0%
    Mar 19
    Reported Apr 1
    		$-0.87$-0.96+9.38%Beat-1350.0%
    Dec 18
    Reported Dec 31
    		$0.34$-0.08+525.00%Beat+61.9%
    Sep 18
    Reported Nov 12
    		$-0.72$-0.96+25.00%Beat-700.0%
    Jun 18
    Reported Aug 9
    		$-0.60$-0.84+28.57%Beat-1400.0%
    Mar 18
    Reported May 11
    		$-0.06N/AN/ABeat+45.5%
    Dec 17
    Reported Mar 21
    		$0.21N/AN/ABeat+100.6%
    Sep 17
    Reported Nov 8
    		$-0.09N/AN/ABeat+90.6%
    Jun 17
    Reported Aug 8
    		$-0.04N/AN/ABeat-
    Mar 17
    Reported Apr 27
    		$-0.11N/AN/ABeat-
    Dec 16
    Reported Dec 31
    		$-33.15N/AN/ABeat-
    Sep 16
    Reported Nov 9
    		$-0.96N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.53EV/EBITDA0.66x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-3032.00%
    ROE-311.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage99.40x
    Current Ratio1.24xQuick Ratio1.24x
    Trading Statistics
    Beta1.43Avg Volume85.71K
    52-Week High$2.0352-Week Low$0.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.13
    SMA 20$1.10
    SMA 50$1.02
    SMA 200$1.09
    EMA 10$1.12
    EMA 20$1.09
    EMA 50$1.06
    EMA 200$1.14

    MACD

    Line: 0.04Signal: 0.04Hist: 0.00

    ADX

    ADX: 15.0+DI: 18.0-DI: 13.7

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down8.0
    PSAR$1.22

    Bollinger Bands

    Upper Band$1.20
    Lower Band$1.00
    %B Position1778%(Upper)
    Band Width0.81

    RSI (14-Day)

    Neutral
    60.9

    Momentum Oscillators

    Stoch %K43.6
    Stoch %D48.0
    Williams %R-41.9
    ROC (10d)6.4%
    Momentum0.07
    CCI (20d)68.3
    MFI (14d)65.4

    Volatility Measures

    ATR (14d)$0.07(6.1%)
    StdDev (20d)0.05
    Hist Vol45.7%(High)

    Volume Flow

    VWAP$1.14
    OBV213.9M
    AD Line-152.2M
    CMF (20d)-0.155

    Volume Metrics

    Avg Vol (20d)69.1K
    Vol Ratio0.7x
    VWMA (20d)$1.10

    Pivot Points

    R3$1.23
    R2$1.21
    R1$1.15
    Pivot Point$1.13
    S1$1.07
    S2$1.05
    S3$0.99

    Advanced Oscillators

    TSI20.14
    Ultimate Osc39.2
    KST171.00

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$105,000$225,000$0$0$0$0$136,000$0$0$0$144,000$0
    Cost of Revenue$0$0$-1,394,000$0$0$0$28,000$0$0$0$4.27M$0
    Gross Profit$105,000$225,000$1.39M$0$0$0$-28,000$0$0$0$-4,267,000$0
    Operating Expenses$3.29M$2.58M$2.48M$2.09M$2.11M$2.34M$3.23M$5.04M$5.45M$4.16M$4.67M$4.44M
    R&D$2.14M$1.37M$1.62M$954,000$1.12M$1.36M$2.04M$3.24M$4.31M$2.95M$4.27M$4.19M
    SG&A$1.15M$1.21M$862,000$1.14M$986,000$981,000$1.19M$1.80M$1.14M$1.21M$1.40M$1.85M
    Operating Income$-3,184,000$-2,356,000$-2,481,000$-2,089,000$-2,108,000$-2,341,000$-3,230,000$-5,042,000$-5,448,000$-4,158,000$-4,666,000$-4,443,000
    Interest Income$0$0$0$0$0$0$0$111,000$151,000$0$0$0
    Interest Expense$-10,000$-22,000$-47,000$-22,000$-28,000$-37,000$36,000$0$0$-220,000$-180,000$-320,000
    Income Before Tax$-3,164,000$-2,299,000$-2,426,000$-2,049,000$-2,055,000$-2,301,000$-3,266,000$-4,939,000$-5,343,000$-3,956,000$-4,464,000$-4,165,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,164,000$-2,299,000$-2,426,000$-2,049,000$-2,055,000$-2,301,000$-3,266,000$-4,939,000$-5,343,000$-3,956,000$-4,464,000$-4,165,000
    EBITDA$-3,162,000$-2,309,000$-2,460,000$-2,058,000$-2,062,000$-2,239,000$-3,293,000$-5,020,000$-5,461,000$-4,141,000$-4,604,000$-4,432,000
    EBIT$-3,174,000$-2,321,000$-2,473,000$-2,071,000$-2,083,000$-2,338,000$-3,321,000$-5,050,000$-5,494,000$-4,176,000$-4,644,000$-4,485,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about COCP

    Government Contracts

    Gov Obligations (TTM)
    $498199
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    1.8 mo

    Top agency: Department of Health and Human Services at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75N93025C00038Department of Health and Human ServicesNational Institutes of Health$498199Sep 29, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Cocrystal Pharma: The Strategic Reset Investors May Be Missing

    Cocrystal Pharma (NASDAQ: COCP) is undergoing a significant strategic reset, led by experienced biotech executive James Sapirstein, who has a strong track record in commercial pharmaceutical leadership and antiviral development. The company, co-founded by Phillip Frost, recently received a $5 million investment from OPKO Health, signaling strong backing from its principal stockholder. This strategic shift, coupled with a strengthened board and a promising antiviral candidate for norovirus, suggests Cocrystal Pharma is positioned for significant value creation despite its current low market capitalization.

    Yahoo Finance•8/31/26•
    Bullish

    Cocrystal (COCP) director Brosgart files with zero reported holdings

    Cocrystal Pharma, Inc. (COCP) director Carol L. Brosgart has filed an initial statement of beneficial ownership on Form 3, indicating her new position on the company's board. The filing reports no share holdings or transactions, and includes a Power of Attorney as an exhibit. This Form 3 establishes a baseline for future insider transaction reporting for Ms. Brosgart.

    Stock Titan•8/22/26•
    Neutral

    Form 8K Cocrystal Pharma Inc For: 18 August By Investing.com

    This article reports that Cocrystal Pharma Inc. filed a Form 8K on August 18. The filing is related to the company's stock, which saw a -1.71% change. Further details of the 8K filing are not provided in the snippet.

    Investing.com Canada•8/19/26•
    Neutral

    Cocrystal Pharma appoints Carol L. Brosgart to board of directors

    Cocrystal Pharma (NASDAQ:COCP) has appointed Carol L. Brosgart to its board of directors, effective August 12, 2026. This appointment comes as the biotech company faces financial challenges, with a market capitalization of $20.8 million and a recent loss per share. The company also recently announced the appointment of James Sapirstein as its new CEO, with previous Co-CEOs transitioning to other roles.

    Investing.com•8/18/26•
    Somewhat-Bearish

    Cocrystal Pharma (NASDAQ: COCP) names Carol L. Brosgart to its board

    Cocrystal Pharma, Inc. (NASDAQ: COCP) has appointed Carol L. Brosgart as a director to its Board, effective August 12, 2026. The company stated that there are no arrangements or understandings related to her selection, no family relationships with current directors or officers, and no related party transactions requiring disclosure. This appointment was reported via an 8-K filing to the SEC.

    Stock Titan•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About COCP

    Does COCP pay dividends?
    Cocrystal Pharma Inc (COCP) does not currently pay a regular dividend.
    What is COCP's market cap?
    Cocrystal Pharma Inc (COCP) has a market capitalization of $21.19M with a current stock price of $1.16.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In